Allogeneic CD19/BCMA CAR-T B cell autoimmune trial
Summary
ClinicalTrials.gov registered a Phase 1/2 clinical trial (NCT07507201) evaluating allogeneic CD19/BCMA CAR-T cell therapy for B cell autoimmune diseases. The dose-escalation study will assess safety, tolerability, and preliminary efficacy in autoimmune patients. Registration includes eligibility criteria, study design, and investigator contact information.
What changed
A new clinical trial registration was added to ClinicalTrials.gov for an allogeneic CAR-T cell therapy study targeting both CD19 and BCMA antigens for B cell-mediated autoimmune diseases. The trial is registered as Phase 1/2 with dose-escalation design. NCT07507201 documents participant eligibility criteria, primary endpoints focused on safety and dose-limiting toxicity, and contact details for the principal investigator.
This is an informational registration entry that does not impose compliance obligations. Clinical investigators and sponsors conducting similar cell therapy research may wish to review the protocol for competitive landscape awareness. Patients seeking enrollment opportunities can reference this trial through ClinicalTrials.gov.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.